Telemetry Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

Telemetry Investments’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$332K	Sell	390,000 -132,009	-25%	-$117K	0.52%	50
2022 Q3	$427K	Buy	522,009 +61,906	+13%	+$59.1K	0.55%	55
2022 Q2	$456K	Buy	460,103 +172,603	+60%	+$212K	0.54%	57
2022 Q1	$472K	Buy	287,500 +94,591	+49%	+$173K	0.74%	51
2021 Q4	$465K	Sell	192,909 -3,259	-2%	-$12.6K	0.6%	56
2021 Q3	$949K	Sell	196,168 -67,807	-26%	-$201K	1.28%	21
2021 Q2	$705K	Buy	263,975 +14,969	+6%	+$41.2K	0.97%	36
2021 Q1	$767K	Buy	249,006 +59,925	+32%	+$216K	0.87%	42
2020 Q4	$673K	Buy	+189,081	New	+$761K	1.14%	33
2019 Q3	–	Sell	-101,218	Closed	-$379K	–	56
2019 Q2	$379K	Sell	101,218 -48,981	-33%	-$192K	0.29%	55
2019 Q1	$604K	Buy	150,199 +15,076	+11%	+$63.6K	0.31%	47
2018 Q4	$496K	Buy	+135,123	New	+$921K	0.32%	75
2017 Q4	–	Sell	-27,000	Closed	-$430K	–	138
2017 Q3	$430K	Buy	+27,000	New	+$374K	0.15%	77

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Telemetry Investments's CRVS Position: Q4 2022 in Review

Telemetry Investments reduced its Corvus Pharmaceuticals (CRVS) stake by 25% in Q4 2022, selling an estimated $117K and leaving 390,000 shares worth $332K. The position accounts for 0.52% of the portfolio, ranked #50.

Telemetry Investments first reported a position in CRVS in Q3 2017 and has held it in 13 quarters since. The position peaked at $949K in Q3 2021. 41 funds tracked by Wall St. Rank hold CRVS as of Q4 2022.

Telemetry Investments held 390,000 shares of Corvus Pharmaceuticals worth $332K as of Q4 2022.
Telemetry Investments sold 132,009 Corvus Pharmaceuticals shares in Q4 2022, an estimated $117K.
Corvus Pharmaceuticals made up 0.52% of Telemetry Investments's portfolio in Q4 2022, its #50 holding.
Telemetry Investments first reported a position in Corvus Pharmaceuticals in Q3 2017 and has held it in 13 quarters since.
Telemetry Investments's Corvus Pharmaceuticals position peaked at $949K in Q3 2021.
41 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2022.

Based on Telemetry Investments's 13F filing for Q4 2022, filed 14 Feb 2023.